GLG News by Silicone Hydrogel and Bausch and Lomb Contact Lens Prescribers: Ophthalmologists and Optometrists (US)

There has been a sea change in the treatment of postoperative cataract patients. The addition of a nonsteroidal has significantly reduced postoperative complications such as edema, discomfort and inflammation.Compliance with all medications is always an issue, and the use of a once daily medication...

Cooper continues to lag behind the competition in the silicone hydrogel market.  They still haven't had a large scale launch of its Biofinity lens and there's no date set.Cooper's lenses have been a staple in my office since I started practicing, but as I transition my patients in the healthier...

It is reported today that AMO will purchase Intralase Corp for 808 million dollars in what could securely position AMO as the world leader in all aspects of LASIK and laser vision correction technology. For months it has been speculated that such a purchase would occur.

While the use of Intacs has practically ended for routine correction of myopia, and the company management and ownership has shifted several times in the last few years, there has been a great interest and success in using these implants for the stabilization of eyes with ectasias such as keratoconus...

Apparently, with only about a dozen other topical ophthalmic allergy medications available in the US, ISTA has decided that the market can bear one more: bepotastine. However, with the imminent release of Alcon's PATADAY - the first once-daily allergy eye drop - and Alimera / B&L's ALAWAY - the...

According to sources at Alcon, the preservation system in Travatan Z (SofZia) is not susceptible to mold growth, as compared to that of Systane Free.

Despite short term patient satisfaction for the correction of myopia, with the multiple problems and issues associated with the approval of the Visian ICL (phakic iol) for correction of myopia over the past several years, and some studies that indicated higher corneal endothelial cell count loss and...

While the authors caution that further studies are required to evaluate the safety and efficacy of Avastin, it is clear that there is a huge interest in this therapy for macular degenration due to its apparent effectivity and relative low cost in relation to other similar anti vgef therapies. ...

It is interesting to see that the government is analyzing the cost of correcting refractive errors in the USA across the entire population. While the military considers it cost effective and safe to offer refractive surgery to a large percentage of its active recruits at a minimal expense to the patient,...

This study demonstrates that many labs are working on finding other new methods to treat earlier forms of macular degeneration before it progresses to the wet form.  The use of hormone replacement, already a common practice since years, may also show to be useful for management of macular dege...